Intellectual property related generic defense strategies in the European pharmaceutical market : : implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective / / Marc P. Philipp.
This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed im...
Saved in:
Superior document: | MIPLC studies ; v. 11 |
---|---|
: | |
TeilnehmendeR: | |
Year of Publication: | 2011 |
Language: | English |
Series: | MIPLC studies ;
v. 11. |
Physical Description: | 1 electronic resource (92 p.) |
Notes: | "Munich Intellectual Property Law Center." |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993544170904498 |
---|---|
lccn |
2012392191 |
ctrlnum |
(CKB)4340000000010145 (oapen)https://directory.doabooks.org/handle/20.500.12854/50417 (EXLCZ)994340000000010145 |
collection |
bib_alma |
record_format |
marc |
spelling |
Philipp, Marc P. Intellectual property related generic defense strategies in the European pharmaceutical market : implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective / Marc P. Philipp. Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market Nomos Verlagsgesellschaft mbH & Co. KG 2011 1 electronic resource (92 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier MIPLC studies ; v. 11 Thesis--Universität München, 2010. Introduction -- Governance framework of Europe's pharmaceutical sector -- Competitive dynamics in Europe's pharmaceutical market -- Potential future limitations for generic defense -- Implications of business model transformations -- Conclusion & managerial recommendation. "Munich Intellectual Property Law Center." Includes bibliographical references (p. 83-91). This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator’s ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry’s final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry’s findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany. English Creative Commons Attribution 4.0 International CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode Description based on print version record; resource not viewed. Unrestricted online access star Drugs Law and legislation European Union countries. Drugs Patents. Generic drugs European Union countries. Antitrust law European Union countries. Wettbewerbsrecht Handels- und Wirtschaftsrecht Kartellrecht 3-8329-6707-9 Munich Intellectual Property Law Center. MIPLC studies ; v. 11. |
language |
English |
format |
Thesis eBook |
author |
Philipp, Marc P. |
spellingShingle |
Philipp, Marc P. Intellectual property related generic defense strategies in the European pharmaceutical market : implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective / MIPLC studies ; Introduction -- Governance framework of Europe's pharmaceutical sector -- Competitive dynamics in Europe's pharmaceutical market -- Potential future limitations for generic defense -- Implications of business model transformations -- Conclusion & managerial recommendation. |
author_facet |
Philipp, Marc P. Munich Intellectual Property Law Center. Munich Intellectual Property Law Center. |
author_variant |
m p p mp mpp |
author2 |
Munich Intellectual Property Law Center. |
author2_role |
TeilnehmendeR |
author_corporate |
Munich Intellectual Property Law Center. |
author_sort |
Philipp, Marc P. |
title |
Intellectual property related generic defense strategies in the European pharmaceutical market : implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective / |
title_sub |
implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective / |
title_full |
Intellectual property related generic defense strategies in the European pharmaceutical market : implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective / Marc P. Philipp. |
title_fullStr |
Intellectual property related generic defense strategies in the European pharmaceutical market : implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective / Marc P. Philipp. |
title_full_unstemmed |
Intellectual property related generic defense strategies in the European pharmaceutical market : implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective / Marc P. Philipp. |
title_auth |
Intellectual property related generic defense strategies in the European pharmaceutical market : implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective / |
title_alt |
Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market |
title_new |
Intellectual property related generic defense strategies in the European pharmaceutical market : |
title_sort |
intellectual property related generic defense strategies in the european pharmaceutical market : implications of the eu commission's sector inquiry from an ip, competition law and economic perspective / |
series |
MIPLC studies ; |
series2 |
MIPLC studies ; |
publisher |
Nomos Verlagsgesellschaft mbH & Co. KG |
publishDate |
2011 |
physical |
1 electronic resource (92 p.) |
contents |
Introduction -- Governance framework of Europe's pharmaceutical sector -- Competitive dynamics in Europe's pharmaceutical market -- Potential future limitations for generic defense -- Implications of business model transformations -- Conclusion & managerial recommendation. |
isbn |
3-8452-3103-3 3-8329-6707-9 |
callnumber-first |
K - Law |
callnumber-label |
KJE6201 |
callnumber-sort |
KJE 46201 P58 42011 |
genre_facet |
Patents. |
geographic_facet |
European Union countries. |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT philippmarcp intellectualpropertyrelatedgenericdefensestrategiesintheeuropeanpharmaceuticalmarketimplicationsoftheeucommissionssectorinquiryfromanipcompetitionlawandeconomicperspective AT munichintellectualpropertylawcenter intellectualpropertyrelatedgenericdefensestrategiesintheeuropeanpharmaceuticalmarketimplicationsoftheeucommissionssectorinquiryfromanipcompetitionlawandeconomicperspective AT philippmarcp intellectualpropertyrelatedgenericdefensestrategiesintheeuropeanpharmaceuticalmarket AT munichintellectualpropertylawcenter intellectualpropertyrelatedgenericdefensestrategiesintheeuropeanpharmaceuticalmarket |
status_str |
n |
ids_txt_mv |
(CKB)4340000000010145 (oapen)https://directory.doabooks.org/handle/20.500.12854/50417 (EXLCZ)994340000000010145 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
MIPLC studies ; v. 11 |
hierarchy_sequence |
v. 11. |
is_hierarchy_title |
Intellectual property related generic defense strategies in the European pharmaceutical market : implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective / |
container_title |
MIPLC studies ; v. 11 |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1797653556624359424 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03985nam-a2200541z--4500</leader><controlfield tag="001">993544170904498</controlfield><controlfield tag="005">20240424230230.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2011 xx |||||o ||| 0|eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a"> 2012392191</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-8452-3103-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4340000000010145</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/50417</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994340000000010145</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">BTCTA</subfield><subfield code="b">eng</subfield><subfield code="c">BTCTA</subfield><subfield code="d">GWL</subfield><subfield code="d">OHX</subfield><subfield code="d">YDXCP</subfield><subfield code="d">DLC</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="042" ind1=" " ind2=" "><subfield code="a">lccopycat</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">e------</subfield></datafield><datafield tag="050" ind1="0" ind2="0"><subfield code="a">KJE6201</subfield><subfield code="b">.P58 2011</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Philipp, Marc P.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intellectual property related generic defense strategies in the European pharmaceutical market :</subfield><subfield code="b">implications of the EU Commission's sector inquiry from an IP, competition law and economic perspective /</subfield><subfield code="c">Marc P. Philipp.</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Nomos Verlagsgesellschaft mbH & Co. KG</subfield><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (92 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">MIPLC studies ;</subfield><subfield code="v">v. 11</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="a">Thesis--Universität München, 2010.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Introduction -- Governance framework of Europe's pharmaceutical sector -- Competitive dynamics in Europe's pharmaceutical market -- Potential future limitations for generic defense -- Implications of business model transformations -- Conclusion & managerial recommendation.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"Munich Intellectual Property Law Center."</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references (p. 83-91).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator’s ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry’s final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry’s findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">Creative Commons Attribution 4.0 International</subfield><subfield code="f">CC BY 4.0</subfield><subfield code="u">https://creativecommons.org/licenses/by/4.0/legalcode</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on print version record; resource not viewed.</subfield></datafield><datafield tag="506" ind1="0" ind2=" "><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="x">Law and legislation</subfield><subfield code="z">European Union countries.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="v">Patents.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Generic drugs</subfield><subfield code="z">European Union countries.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Antitrust law</subfield><subfield code="z">European Union countries.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Wettbewerbsrecht</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Handels- und Wirtschaftsrecht</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Kartellrecht</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-8329-6707-9</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Munich Intellectual Property Law Center.</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">MIPLC studies ;</subfield><subfield code="v">v. 11.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2024-04-26 03:11:37 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2016-07-09 16:49:08 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337553800004498&Force_direct=true</subfield><subfield code="Z">5337553800004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337553800004498</subfield></datafield></record></collection> |